Clinical and serum-based markers are associated with death within 1 year of de novo implant in primary prevention ICD recipients

Heart Rhythm

Volumn 12, Issue 2, 2015, Pages 360-366

  Zhang, Yiyi ^a   Guallar, Eliseo ^a   Blasco Colmenares, Elena ^b   Dalal, Darshan ^b   Butcher, Barbara ^b   Norgard, Sanaz ^b   Tjong, Fleur V Y ^c   Eldadah, Zayd ^d   Dickfeld, Timm ^e   Ellenbogen, Kenneth A ^f   Marine, Joseph E ^b   Tomaselli, Gordon F ^b   Cheng, Alan ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Earlymortality; ICDshock; Implantablecardioverter defibrillator; Primaryprevention; Sudden cardiacdeath

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR II; UNCLASSIFIED DRUG; CREATINE KINASE MB; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CARDIOMYOPATHY; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; DEFIBRILLATION; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; PATIENT COUNSELING; PATIENT SELECTION; PHENOTYPE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STATISTICAL ANALYSIS; SUDDEN CARDIAC DEATH; BLOOD; CLINICAL TRIAL; DEATH, SUDDEN, CARDIAC; HEART FAILURE; INCIDENCE; NETHERLANDS; PROCEDURES; PROGNOSIS; SURVIVAL RATE; TRENDS; UNITED STATES;

AGED; BIOMARKERS; CREATINE KINASE, MB FORM; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NETHERLANDS; PEPTIDE FRAGMENTS; PRIMARY PREVENTION; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TROPONIN T; UNITED STATES;

EID: 84921301119     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2014.10.034     Document Type: Article

References (25)

1. A.J. Moss, W. Zareba, W.J. Hall, H. Klein, D.J. Wilber, D.S. Cannom, J.P. Daubert, S.L. Higgins, M.W. Brown, and M.L. Andrews Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction N Engl J Med 346 2002 877 883
2. G.H. Bardy, K.L. Lee, and D.B. Mark Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 2005 225 237
3. A.E. Buxton, K.L. Lee, J.D. Fisher, M.E. Josephson, E.N. Prystowsky, and G. Hafley Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease N Engl J Med 341 1999 1882 1890
4. A. Kadish, A. Dyer, and J.P. Daubert Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy N Engl J Med 350 2004 2151 2158
5. A.E. Epstein, J.P. DiMarco, and K.A. Ellenbogen ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons Circulation 117 2008 e350 e408
6. C.M. Tracy, A.E. Epstein, and D. Darbar 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [corrected] Circulation 126 2012 1784 1800
7. K. Kraaier, M.F. Scholten, J.G. Tijssen, D.A. Theuns, L.J. Jordaens, A.A. Wilde, and P.F. van Dessel Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score Europace 16 2014 40 46
8. R. Parkash, W.G. Stevenson, L.M. Epstein, and W.H. Maisel Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection Am Heart J 151 2006 397 403
9. K.M. Stein, S. Mittal, F.R. Gilliam, D.M. Gilligan, Q. Zhong, S.M. Kraus, and T.E. Meyer Predictors of early mortality in implantable cardioverter-defibrillator recipients Europace 11 2009 734 740
10. D. Ertel, K. Phatak, K. Makati, M. Holland, S. Baig, M.H. Kim, M. Link, and R. Passman Predictors of early mortality in patients age 80 and older receiving implantable defibrillators Pacing Clin Electrophysiol 33 2010 981 987
11. C.W. Kao, E. Friedmann, and S.A. Thomas Quality of life predicts one-year survival in patients with implantable cardioverter defibrillators Qual Life Res 19 2010 307 315
12. D.B. Kramer, P.A. Friedman, L.M. Kallinen, T.B. Morrison, D.J. Crusan, D.O. Hodge, M.R. Reynolds, and R.G. Hauser Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators Heart Rhythm 9 2012 42 46
13. D. Chong, B.Y. Tan, K.L. Ho, R. Liew, W.S. Teo, and C.K. Ching Clinical markers of organ dysfunction associated with increased 1-year mortality post-implantable cardioverter defibrillator implantation Europace 15 2013 508 514
14. J. Kobe, K. Wasmer, D. Andresen, T. Kleemann, S.G. Spitzer, J. Jehle, J. Brachmann, C. Stellbrink, M. Hochadel, J. Senges, H.U. Klein, and L. Eckardt Impact of atrial fibrillation on early complications and one year-survival after cardioverter defibrillator implantation: results from the German DEVICE registry Int J Cardiol 168 2013 4184 4190
15. S.P. Bhavnani, C.I. Coleman, D. Guertin, R.K. Yarlagadda, C.A. Clyne, and J. Kluger Evaluation of the Charlson comorbidity index to predict early mortality in implantable cardioverter defibrillator patients Ann Noninvasive Electrocardiol 18 2013 379 388
16. A. Cheng, D. Dalal, B. Butcher, S. Norgard, Y. Zhang, T. Dickfeld, Z.A. Eldadah, K.A. Ellenbogen, E. Guallar, and G.F. Tomaselli Prospective observational study of implantable cardioverter-defibrillators in primary prevention of sudden cardiac death: study design and cohort description J Am Heart Assoc 2 2013 e000083
17. C.S. Hager, S. Jain, J. Blackwell, B. Culp, J. Song, and C.D. Chiles Effect of renal function on survival after implantable cardioverter defibrillator placement Am J Cardiol 106 2010 1297 1300
18. P.S. Cuculich, J.M. Sanchez, R. Kerzner, S.L. Greenberg, J. Sengupta, J. Chen, M.N. Faddis, M.J. Gleva, T.W. Smith, and B.D. Lindsay Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death Pacing Clin Electrophysiol 30 2007 207 213
19. A. Deswal, N.J. Petersen, A.M. Feldman, J.B. Young, B.G. White, and D.L. Mann Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST) Circulation 103 2001 2055 2059
20. S.M. Dunlay, S.A. Weston, M.M. Redfield, J.M. Killian, and V.L. Roger Tumor necrosis factor-alpha and mortality in heart failure: a community study Circulation 118 2008 625 631
21. T.S. Rodriguez-Reyna, O. Arrieta, L. Castillo-Martinez, A. Orea-Tejeda, P. Guevara, V. Rebollar, and J. Granados Tumour necrosis factor alpha and troponin T as predictors of poor prognosis in patients with stable heart failure Clin Invest Med 28 2005 23 29
22. E. Braunwald Biomarkers in heart failure N Engl J Med 358 2008 2148 2159
23. K. Maeda, T. Tsutamoto, A. Wada, N. Mabuchi, M. Hayashi, T. Tsutsui, M. Ohnishi, M. Sawaki, M. Fujii, T. Matsumoto, and M. Kinoshita High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure J Am Coll Cardiol 36 2000 1587 1593
24. M.P. Hudson, C.M. O'Connor, W.A. Gattis, G. Tasissa, V. Hasselblad, C.M. Holleman, L.H. Gaulden, F. Sedor, and E.M. Ohman Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis Am Heart J 147 2004 546 552
25. Y. Nakamura, A. Yoshihisa, and M. Takiguchi High-sensitivity cardiac troponin T predicts non-cardiac mortality in heart failure Circ J 78 2014 890 895